Effect of Dextran on Factor Vlll/von Willebrand Factor Structure and Function

Summary

Factor VIII/von Willebrand factor was analyzed before and after the infusion of 500 ml of Dextran 70 to normal volunteers. Factor VIII procoagulant activity, factor VIII related antigen and ristocetin cofactor activity showed a significant decrease, reaching after six hours the minimum level, which did not correlate with the hemodilution effect caused by dextran. Ristocetin-induced platelet agglutination (RIPA) in volunteers’ platelet-rich plasma (PRP) did not show any significant change between preinfusion time and six hours after the infusion. Multimeric analysis of von Willebrand factor (vWF) showed a progressive decrease of all the multimers which was more pronounced in the largest multimers. No change was seen in the “triplet” structure of vWF. No effect was noticed when dextran was incubated “in vitro” either with PRP or platelet-poor plasma. The modification induced by dextran is close to the pattern seen in subtype Ib von Willebrand’s disease.

Keywords

Dextran - Factor VIII/vWF - vWF multimeric structure

• References

• 1 Aberg M, Hedner U, Bergentz SE. Effect of dextran on factor VIII (antihemophilic factor) and platelet function. Ann Surg 1979; 189: 243-247
• 2 Hoyer LW, Shainoff JR. Factor VUI-related protein circulates in normal plasma as high molecular weight multimers. Blood 1980; 55: 1056-1059
• 3 Meyer D, Obert B, Pietu G, Lavergne JM, Zimmerman TS. Multimeric structure of factor Vlll/von Willebrand factor in von Willebrand’s disease. J Lab Clin Med 1980; 95: 590-602
• 4 Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric composition of factor Vlll/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-1325
• 5 Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor Vlll/von Willebrand factor. Blood 1981; 57: 1140-1143
• 6 Counts RB, Paskell SL, Elge SK. Disulfide bonds and the quaternary structure of factor Vlll/von Willebrand factor. J Clin Invest 1978; 62: 702-709
• 7 Van Mourik JA, Bouma BN, La Bruyere WT, De Graaf S, Mochtar IA. Factor VIII as a series of homologous oligomers and a complex of two proteins. Thromb Res 1974; 4: 155-164
• 8 Zimmerman TS, Ruggeri ZM, Fulcher C. Factor Vlll/von Willebrand factor. Progress in Haematology Brown EB. (Ed) 279-309 Grune & Stratton; Orlando, Fla: 1983
• 9 Hoyer LW, Rizza CR, Tuddenham EG, Carta CA, Armitage H, Rotblat F. Von Willebrand factor multimers in von Willebrand’s disease. Br J Haematol 1983; 55: 493-507
• 10 Zimmerman TS, Batlle FJ, Ruggeri ZM, Roberts JR. Multimeric analysis of factor Vlll/von Willebrand factor in the diagnosis of von Willebrand’s disease. Clinical Laboratory Assays: New technology and future directions Nakamura RM, Dito WR, Tucker ES. (Ed) 249-263 Masson Publishing USA Inc; New York: 1983
• 11 Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests. J Lab Clin Med 1953; 41: 637
• 12 Ingram GI. Blood coagulation factor VIII: genetics, physiological control and bioassay. Adv Clin Chem 1956; 8: 101-112
• 13 Zimmerman TS, Roberts JR. Factor VIII related antigen. Immunoassays: Clinical Laboratory Techniques for the 1980’s Nakamura RM, Dito WR, Tucker ES. (Ed) pp9-49 Alan R. Liss, Inc; Nwe York: 1980
• 14 Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (ristocetin cofactor). Thrombos Diathes Haemorrh 1975; 34: 306-308
• 15 Italian Working Group. Spectrum of von Willebrand’s disease: a study of 100 cases. Br J Haematol 1977; 35: 101-112
• 16 Bergqvist D. Dextran and haemostasis. Acta Chirur Scand 1982; 148: 633-640
• 17 Over J, Sixma JJ, Doucet-de Bruine MH, Trieschingg AM, Vlooswijk RA, Beeser-Visser NH, Bouma BN. Survival of ¹²⁵Iodine labeled factor VIII in normals and patients with classic Hemophilia. Observations on the heterogeneity of human factor VIII. J Clin Invest 1978; 62: 223-234